Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on Vanda Pharmaceuticals, with six buy, two hold and one sell rating among nine analysts. The average 12-month price target is $13.08, well above the stock’s recent $4.81 price.
• Vanda reported a quarterly loss of $1.04 per share, missing the $0.58 consensus estimate, while revenue of $50.53 million fell short of the $61.92 million forecast. Analysts expect a full-year loss of approximately $3.02 per share.
• The stock has declined toward its 52-week low, trading below both its 50-day and 200-day moving averages, while institutional investors own 88.14% of outstanding shares.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $13.08.

Several equities analysts have recently issued reports on the company. HC Wainwright decreased their price target on Vanda Pharmaceuticals from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. B. Riley Financial restated a "buy" rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Finally, Oppenheimer initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an "outperform" rating and a $10.00 target price on the stock.

Vanda Pharmaceuticals Stock Performance

VNDA stock opened at $4.81 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60. The company has a 50 day moving average price of $5.20 and a 200 day moving average price of $6.06. Vanda Pharmaceuticals has a fifty-two week low of $4.27 and a fifty-two week high of $9.94. The stock has a market capitalization of $290.81 million, a PE ratio of -1.04 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.46). The firm had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. Analysts forecast that Vanda Pharmaceuticals will post -3.02 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of VNDA. Hsbc Holdings PLC boosted its holdings in Vanda Pharmaceuticals by 8.8% during the first quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company's stock worth $261,000 after buying an additional 3,144 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $29,000. Legal & General Group Plc bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $34,000. Allworth Financial LP bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $43,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Vanda Pharmaceuticals by 3,010.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company's stock valued at $92,000 after acquiring an additional 10,055 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders involving the central nervous system and circadian rhythm. Founded in 2003 and headquartered in Washington, DC, the company conducts clinical development, regulatory, and commercial activities primarily in the United States, with efforts to make its products available in additional markets where approved.

Vanda's marketed products include Hetlioz (tasimelteon), a melatonin-receptor agonist approved for the treatment of Non-24-Hour Sleep-Wake Disorder in adults who are totally blind and for nighttime sleep disturbances in certain patients with Smith-Magenis syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.